IIM
AVBP icon

INTECH Investment Management’s ArriVent BioPharma AVBP Stock Holding History

INTECH Investment Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$273K Buy
11,819
+812
+7% +$18.3K ﹤0.01% 1606
2025
Q4 		$221K Buy
+11,007
New +$229K ﹤0.01% 1931
2025
Q3 		– Sell
-13,461
Closed -$293K – 2533
2025
Q2 		$293K Sell
13,461
-4,608
-26% -$95.7K ﹤0.01% 1873
2025
Q1 		$334K Buy
18,069
+3,271
+22% +$80K ﹤0.01% 1822
2024
Q4 		$394K Buy
+14,798
New +$425K ﹤0.01% 1691

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

INTECH Investment Management's AVBP Position: Q1 2026 in Review

INTECH Investment Management increased its ArriVent BioPharma (AVBP) stake by 7.4% in Q1 2026, buying an estimated $18.3K and bringing the position to 11,819 shares worth $273K. The position accounts for ﹤0.01% of the portfolio, ranked #1606.

INTECH Investment Management first reported a position in AVBP in Q4 2024 and has held it in 5 quarters since. The position peaked at $394K in Q4 2024. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • INTECH Investment Management held 11,819 shares of ArriVent BioPharma worth $273K as of Q1 2026.
  • INTECH Investment Management bought 812 ArriVent BioPharma shares in Q1 2026, an estimated $18.3K.
  • ArriVent BioPharma made up ﹤0.01% of INTECH Investment Management's portfolio in Q1 2026, its #1606 holding.
  • INTECH Investment Management first reported a position in ArriVent BioPharma in Q4 2024 and has held it in 5 quarters since.
  • INTECH Investment Management's ArriVent BioPharma position peaked at $394K in Q4 2024.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on INTECH Investment Management's 13F filing for Q1 2026, filed 8 May 2026.